Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax (NVAX) reported encouraging Phase 1 data for its COVID-19 vaccine, NVX-CoV2373, demonstrating superior neutralization levels and strong immune responses. The company secured $2 billion funding from CEPI, DoD, and OWS, enhancing its operational capacity and collaborations with Takeda and Serum Institute. Financial results show a significant revenue increase to $35.5 million for Q2 2020, compared to $3.4 million in Q2 2019, alongside a reduced net loss of $17.5 million. Novavax continues to strengthen its leadership team and expand manufacturing capabilities for vaccine production.
Novavax has partnered with Takeda to license its COVID-19 vaccine technology, NVX-CoV2373, for production and commercialization in Japan. The Government of Japan will fund Takeda for technology transfer and infrastructure setup, enabling the manufacture of over 250 million doses annually. Novavax will supply the proprietary Matrix-M adjuvant. The collaboration aims to enhance pandemic preparedness and expand vaccine availability in Japan, with Novavax set to receive milestone payments and a share of the vaccine proceeds.
Novavax, Inc. (Nasdaq: NVAX) has entered a license agreement with Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373, in low- and middle-income countries (LMIC) and India. The partnership aims to ensure a global supply of the vaccine, leveraging Serum Institute's extensive reach. Serum Institute gains exclusive commercialization rights in India and shared rights in other LMICs. The collaboration builds on Novavax's efforts with CEPI for equitable vaccine distribution through the COVAX Facility.
Novavax, a late-stage biotechnology company, will release its second quarter 2020 financial results on August 10, 2020, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET, with dial-in numbers provided for domestic and international participants. The call will cover latest updates on Novavax's vaccine candidates, including NVX-CoV2373 for COVID-19 and NanoFlu, their influenza vaccine. Investors can access a webcast of the call and a replay available until August 17, 2020.
Novavax (NVAX) announced promising Phase 1 data for its COVID-19 vaccine candidate, NVX-CoV2373, which was generally well-tolerated and exhibited a reassuring safety profile. The trial involved 131 healthy adults aged 18-59 and demonstrated that 100% of participants achieved neutralization titers. Both 5 µg and 25 µg doses generated peak geometric mean titers exceeding 1:3,300. The Matrix-M adjuvant contributed to strong immune responses. The data will be submitted for peer review and available via a preprint server.
On July 23, 2020, Novavax (NASDAQ: NVAX) announced a collaboration with FUJIFILM Diosynth Biotechnologies for the large-scale manufacturing of its COVID-19 vaccine candidate, NVX-CoV2373, following a $1.6 billion funding award from Operation Warp Speed. The production has commenced in Morrisville, North Carolina, with the initial batch for upcoming Phase 3 clinical trials involving 30,000 subjects. The funding will also support clinical development, aiming to deliver 100 million doses by late 2020. Preliminary results from an ongoing Phase 1/2 trial in Australia are expected soon.
Novavax, Inc. (NASDAQ: NVAX) has partnered with FUJIFILM Diosynth Biotechnologies to manufacture bulk drug substance for its COVID-19 vaccine candidate, NVX-CoV2373. This collaboration is part of Novavax’s $1.6 billion funding from the U.S. government’s Operation Warp Speed, aimed at providing millions of vaccine doses by late 2020. Initial production has begun at FUJIFILM’s North Carolina facility, supporting a pivotal Phase 3 clinical trial expected to start in fall 2020. The vaccine is based on proprietary nanoparticle technology and aims to demonstrate safety and efficacy through extensive trials.
Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D. will present on the progress of NVX-CoV2373, its COVID-19 vaccine candidate, at the 2nd International Society for Vaccines Virtual Congress on July 21, 2020, at 9:55 a.m. ET. The NVX-CoV2373 vaccine is designed using recombinant nanoparticle technology and is funded by the U.S. Government with up to $1.6 billion through Operation Warp Speed. The Phase 1 clinical trial commenced in May 2020, with preliminary results expected in July 2020.
Novavax, Inc. (Nasdaq: NVAX) announced its selection for Operation Warp Speed, receiving a $1.6 billion award to advance its COVID-19 vaccine, NVX-CoV2373. This funding will support late-stage clinical trials, including a pivotal Phase 3 trial with up to 30,000 subjects, and large-scale manufacturing of 100 million doses. Preliminary safety results from a Phase 1/2 trial are expected by late July 2020, with additional support from CEPI amounting to $388 million. This partnership aims to expedite vaccine delivery amid the COVID-19 pandemic.
Novavax, Inc. (NASDAQ: NVAX) announced the appointment of Frank Czworka as Senior Vice President, Global Sales, and the promotion of Brian Webb to Senior Vice President, Manufacturing. Czworka, with over 20 years of experience, has previously held senior roles in biopharmaceutical sales and marketing. Webb has been instrumental in expanding manufacturing capabilities. The company aims to advance its COVID-19 vaccine candidate, NVX-CoV2373, and its quadrivalent influenza nanoparticle vaccine, NanoFlu, to the market, intending to positively impact global health.